Alligator Bioscience AB (publ) (ATORX.ST)
SEK 0.27
(-3.79%)
SEK 0.27
(-3.79%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -160.68 Million SEK | -43.43% |
| 2022 | -112.02 Million SEK | -51.31% |
| 2021 | -74.03 Million SEK | 5.04% |
| 2020 | -77.96 Million SEK | 44.71% |
| 2019 | -141.01 Million SEK | -49.69% |
| 2018 | -94.2 Million SEK | -275.52% |
| 2017 | 53.67 Million SEK | -3.62% |
| 2016 | 55.68 Million SEK | -78.48% |
| 2015 | 258.75 Million SEK | 693.36% |
| 2014 | -43.6 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -26.76 Million SEK | 25.75% |
| 2024 Q3 | 1.43 Million SEK | 105.35% |
| 2024 Q1 | -36.04 Million SEK | 22.74% |
| 2023 Q3 | -33.05 Million SEK | 15.44% |
| 2023 Q2 | -39.09 Million SEK | 37.63% |
| 2023 FY | -160.68 Million SEK | -43.43% |
| 2023 Q1 | -62.68 Million SEK | -129.47% |
| 2023 Q4 | -46.66 Million SEK | -41.15% |
| 2022 Q1 | -24.79 Million SEK | -26.73% |
| 2022 FY | -112.02 Million SEK | -51.31% |
| 2022 Q4 | -27.31 Million SEK | 12.54% |
| 2022 Q3 | -31.23 Million SEK | -22.07% |
| 2022 Q2 | -25.58 Million SEK | -3.21% |
| 2021 FY | -74.03 Million SEK | 5.04% |
| 2021 Q2 | -16.21 Million SEK | 4.75% |
| 2021 Q3 | -21.23 Million SEK | -30.98% |
| 2021 Q4 | -19.56 Million SEK | 7.9% |
| 2021 Q1 | -17.02 Million SEK | 12.79% |
| 2020 Q2 | -15.8 Million SEK | 37.02% |
| 2020 Q3 | -17.1 Million SEK | -8.21% |
| 2020 FY | -77.96 Million SEK | 44.71% |
| 2020 Q4 | -19.52 Million SEK | -14.13% |
| 2020 Q1 | -25.09 Million SEK | 39.25% |
| 2019 Q2 | -29.99 Million SEK | -7.54% |
| 2019 FY | -141.01 Million SEK | -49.69% |
| 2019 Q4 | -41.3 Million SEK | 1.25% |
| 2019 Q3 | -41.82 Million SEK | -39.45% |
| 2019 Q1 | -27.89 Million SEK | -103.8% |
| 2018 Q3 | -27.36 Million SEK | -18.35% |
| 2018 Q4 | -13.68 Million SEK | 49.99% |
| 2018 Q1 | -29.99 Million SEK | -204.0% |
| 2018 FY | -94.2 Million SEK | -275.52% |
| 2018 Q2 | -23.12 Million SEK | 22.9% |
| 2017 Q3 | -15.37 Million SEK | 16.6% |
| 2017 FY | 53.67 Million SEK | -3.62% |
| 2017 Q1 | -10.23 Million SEK | -17.79% |
| 2017 Q2 | -18.43 Million SEK | -80.19% |
| 2017 Q4 | 28.84 Million SEK | 287.6% |
| 2016 Q2 | -17.63 Million SEK | -156.88% |
| 2016 Q1 | 31 Million SEK | 278.69% |
| 2016 FY | 55.68 Million SEK | -78.48% |
| 2016 Q4 | -8.68 Million SEK | -171.41% |
| 2016 Q3 | -3.2 Million SEK | 81.85% |
| 2015 FY | 258.75 Million SEK | 693.36% |
| 2015 Q3 | 279.69 Million SEK | 0.0% |
| 2015 Q4 | -17.34 Million SEK | -106.2% |
| 2014 FY | -43.6 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ziccum AB (publ) | -23.28 Million SEK | -590.05% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 146.398% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 484.533% |
| Mendus AB (publ) | 28.48 Million SEK | 664.064% |
| Genovis AB (publ.) | 54 Million SEK | 397.559% |
| Intervacc AB (publ) | -13.79 Million SEK | -1064.891% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 7501.428% |
| Active Biotech AB (publ) | -1.67 Million SEK | -9493.134% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 1712.817% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 699.101% |
| Aptahem AB (publ) | 2.63 Million SEK | 6208.191% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -4597.018% |
| Kancera AB (publ) | -1.96 Million SEK | -8077.354% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 208781.818% |
| Fluicell AB (publ) | 1.73 Million SEK | 9345.397% |
| Saniona AB (publ) | 11.78 Million SEK | 1463.933% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -3040.219% |
| Biovica International AB (publ) | 6.87 Million SEK | 2436.557% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | -590.139% |
| AcouSort AB (publ) | 8.38 Million SEK | 2015.425% |
| Xintela AB (publ) | 78 Thousand SEK | 206106.41% |
| Abliva AB (publ) | -35.66 Million SEK | -350.565% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | -9.384% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 5824.439% |
| OncoZenge AB (publ) | 3000.00 SEK | 5356266.667% |
| Amniotics AB (publ) | -1.93 Million SEK | -8225.648% |
| 2cureX AB (publ) | -37.48 Million SEK | -328.642% |
| CombiGene AB (publ) | -21.29 Million SEK | -654.72% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -37886.998% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 114.222% |
| Camurus AB (publ) | 1.58 Billion SEK | 110.167% |
| Corline Biomedical AB | 28.38 Million SEK | 666.191% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | -30.921% |
| Isofol Medical AB (publ) | -34.41 Million SEK | -366.904% |
| I-Tech AB | 27.56 Million SEK | 682.91% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 326.473% |
| Cyxone AB (publ) | 2.61 Million SEK | 6254.155% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 4821.863% |
| Biosergen AB | -456 Thousand SEK | -35137.939% |
| Cantargia AB (publ) | -3.45 Million SEK | -4556.187% |
| NextCell Pharma AB | -43.74 Million SEK | -267.296% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -1647.716% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 1532.349% |
| Nanologica AB (publ) | -76 Thousand SEK | -211327.632% |
| SynAct Pharma AB | -778 Thousand SEK | -20553.599% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -83156.477% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | -1143.499% |
| Lipum AB (publ) | 53 Thousand SEK | 303279.245% |
| BioInvent International AB (publ) | 71.46 Million SEK | 324.857% |
| Alzinova AB (publ) | 19.87 Million SEK | 908.519% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 542.671% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 11083.103% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -1071133.333% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 9791.496% |
| Simris Alg AB (publ) | 2 Million SEK | 8106.228% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -4388.408% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 554.066% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -15217.922% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 5228.79% |